Tenosynovial Giant Cell Tumor clinical trials

Explore recruiting tenosynovial giant cell tumor clinical trials.

Recruiting tenosynovial giant cell tumor studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Tenosynovial Giant Cell Tumor trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor (MOTION)

Germany, Netherlands, France, Spain, Italy, Norway +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-Label, Adaptive, Dose-Ranging Study with Long-Term Extension to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intra-articular AMB-05X Injections in Subjects with Tenosynovial Giant Cell Tumor

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients with Tenosynovial Giant Cell Tumor

Italy, Spain, France, Netherlands, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

Spain, France, Italy, Poland, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A clinical trial to learn how an investigational drug (vimseltinib) is absorbed, distributed, broken down, and removed from the body when given to people with liver problems

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

Tenosynovial Giant Cell Tumor trials by city

Tenosynovial Giant Cell Tumor in Toronto Tenosynovial Giant Cell Tumor in Vancouver Tenosynovial Giant Cell Tumor in Montreal Tenosynovial Giant Cell Tumor in Calgary Tenosynovial Giant Cell Tumor in Edmonton Tenosynovial Giant Cell Tumor in Ottawa Tenosynovial Giant Cell Tumor in Winnipeg Tenosynovial Giant Cell Tumor in Quebec City Tenosynovial Giant Cell Tumor in Hamilton Tenosynovial Giant Cell Tumor in Kitchener Tenosynovial Giant Cell Tumor in London Tenosynovial Giant Cell Tumor in Halifax Tenosynovial Giant Cell Tumor in New York Tenosynovial Giant Cell Tumor in Los Angeles Tenosynovial Giant Cell Tumor in Chicago Tenosynovial Giant Cell Tumor in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease